Combining Behavioral Treatment With Agonist Maintenance - 1

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2008 by National Institute on Drug Abuse (NIDA). Recruitment status was Active, not recruiting

First Received on September 20, 1999. Last Updated on October 27, 2008 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000311

Purpose

The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.

Condition	Intervention	Phase
Cocaine-Related Disorders Opioid-Related Disorders Substance-Related Disorders	Drug: Buprenorphine	Phase III

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Combining Behavioral Treatment With Agonist Maintenance

Resource links provided by NLM:

MedlinePlus related topics: Drug Abuse

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Depression
Withdrawal symptoms
Opioid and cocaine use
Social and psychological functioning
AIDS risk behavior

Estimated Enrollment:	168
Study Start Date:	September 1999

Arms	Assigned Interventions
Experimental: 1 Therapeutic Contracting (TC)	Drug: Buprenorphine Experimental Therapeutic Contracting (TC) Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
Experimental: 2 Cognitive Behavioral Coping Skills Therapy (CBT)	Drug: Buprenorphine Experimental Therapeutic Contracting (TC) Experimental Cognitive Behavioral Coping Skills Therapy (CBT)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000311

Locations

United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Richard Schottenfeld, M.D.

Yale University

More Information

No publications provided

Responsible Party:	Richard S. Schottenfeld, MD, Yale University School of Medicine
ClinicalTrials.gov Identifier:	NCT00000311 History of Changes
Other Study ID Numbers:	NIDA-09413-1, R01-09413-1
Study First Received:	September 20, 1999
Last Updated:	October 27, 2008
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Opioid-Related Disorders
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents

Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on February 09, 2012